Toronto SmallCap

Soin Neuroscience Constructs Spinal Cord Stimulator for Chronic Pain Treatment

Soin Neuroscience Inc., based in Dayton, OH, has recently created a new spinal cord stimulation device (SNI) to treat chronic pain. SNI is an investigational device that has shown significant promise compared to current standard techniques. 

Soin Neuroscience is using a new algorithm and working on a platform that will use machine learning and AI technology to bring precision. 

Because Soin Neuroscience is concerned with excessive opioid use in chronic pain patients, they have developed a different approach to pain by obstructing the nerves that cause pain, using a new algorithm that treats and blocks the nerve using stimulation. The company has recently started human proof of concept studies. 

Spinal cord stimulation requires that the medical device be placed into the spine’s epidural space with leads or wires. Electrical stimulation is then administered to the spine to decrease a patient’s perception of pain. 

Soin Neuroscience is also working on a platform that will use machine learning and AI technology with its medical devices to enhance patient care and bring precision medicine to spinal cord stimulation. 

CEO and founder of Soin Neuroscience, Dr. Soin, says he is eager to start a program dedicated to treating patients who suffer from chronic pain. “As we embark on our journey of science, learning, and development, we believe there may be some significant advantages to our device over the current standard,” Dr. Soin states.

Patients in Dayton, OH, who have tested the device report a substantial reduction in pain. Patients who have tested the new system noted that pain scores went down to a 0 – 2 out of 10. The patients also reported that they were able to stand again for prolonged periods. Another patient stated that their pain score dropped to 0 out of 10 periodically during testing, stating that it felt like a much better option than the shots they were currently using for the pain. 

Dr. Soin is encouraged by the results and believes they may have a breakthrough product for patients dealing with chronic pain. “Although further testing will be needed, the new approach is more in line with how the body’s nerves process information,” Dr. Soin states. “It’s too early to conclude just based on early testing, but our team is excited about the possibilities.” 

Soin Neuroscience has already experienced great success in creating various types of pharmacological agents to treat pain. 

The goal for Soin Neuroscience is to continue developing spinal cord stimulation technology and expand into other types of neurostimulation devices. Soin Neuroscience has already experienced great success in creating various types of pharmacological agents to treat pain. 

The spinal cord stimulation medical device indicates the company’s progress towards meeting the needs of those suffering from chronic pain by offering different modalities. The device is investigational and not FDA approved for use in humans, and patients who have trialed the system are part of an approved early pilot study. 

The device is not available for commercial use. Given that only initial testing has been completed, Soin Neuroscience cannot claim the efficacy of the device as further testing is needed. As a result, there are no guarantees or claims of effectiveness, and further testing is required. 

Email Amol Soin at drsoin@soinneuroscience.com